Palliative care options for patients with terminal haematological diseases, and consultation with palliative care and psychosocial services

Overview

Palliative care in haematological malignancy addresses the same symptom-control and quality-of-life principles as in solid organ malignancy (see the oncology and palliative medicine notes), with some haematology-specific considerations around transfusion support, infection risk, and the sometimes rapid, unpredictable trajectory of advanced haematological disease
Early palliative care integration is increasingly recognised as valuable in haematological malignancy, similar to solid tumours, though historically palliative care referral has occurred later in haematology than in many solid tumour contexts, partly reflecting the less predictable disease trajectory and ongoing availability of further treatment lines

Advanced haematological malignancy can progress rapidly and less predictably than many solid tumours, complicating prognostication and the timing of transitioning from disease-directed to palliative-predominant care - this unpredictability is itself a recognised barrier to timely palliative care integration

Symptom assessment follows standard palliative principles (see pathophysiology of pain) with additional attention to haematology-specific symptom complexes - bleeding/bruising (thrombocytopenia), recurrent infection (neutropenia), and transfusion-dependent fatigue

Transfusion support (red cells, platelets) can be continued as a purely symptom-directed palliative measure even once disease-directed treatment has stopped, distinct from most solid tumour palliative care - the decision to continue or stop transfusion support should be individualised around the patient's goals and the burden/benefit of ongoing hospital visits for transfusion
Early, proactive palliative care involvement (alongside active treatment, not only once treatment options are exhausted) improves symptom control and quality of life, consistent with the broader oncology evidence base

Transfusion-dependent advanced haematological malignancy, infection risk management in palliative-phase neutropenia, prognostication challenges in haematological malignancy

The decision around continuing transfusion support in advanced, palliative-phase haematological malignancy is a genuinely haematology-specific palliative care question without a direct solid-tumour equivalent - it requires individualised discussion of the burden (repeated hospital visits) against the benefit (symptom relief from anaemia/thrombocytopenia) specific to the patient's goals and circumstances

5 more sections, plus exam facts

Premium unlocks every note across every specialty, and the full exam fact library behind it.